Bg pattern

HARVONI 90 mg/400 mg FILM-COATED TABLETS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use HARVONI 90 mg/400 mg FILM-COATED TABLETS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Harvoni 90 mg/400 mg film-coated tablets

Harvoni 45 mg/200 mg film-coated tablets

ledipasvir/sofosbuvir

This medicine is subject to additional monitoring, which will help to quickly identify new safety information. You can contribute by reporting any side effects you may get. The last section of the leaflet includes information on how to report side effects.

Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack and other information

  1. What is Harvoni and what is it used for
  2. What you need to know before you take Harvoni
  1. How to take Harvoni
  2. Possible side effects
  3. Storage of Harvoni
  1. Contents of the pack and other information

If Harvoni has been prescribed to your child, please note that all the information in this leaflet is intended for your child (in that case, read ‘your child’ instead of ‘you’).

1. What is Harvoni and what is it used for

Harvoni is a medicine that contains the active substances ledipasvir and sofosbuvir. Harvoni is used to treat long-term hepatitis C virus infection in adultsand children aged 3 years and older.

Hepatitis C is a viral infection of the liver. The active substances in the medicine work together by blocking two different proteins that the virus needs to grow and multiply, allowing the infection to be eliminated from the body.

Harvoni is sometimes taken with another medicine: ribavirin.

It is very important that you also read the package leaflets of any other medicines that you are taking with Harvoni. If you have any questions about your medicines, ask your doctor or pharmacist.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you take Harvoni

Do not take Harvoni

  • If you are allergicto ledipasvir, sofosbuvir or any of the other ingredients of this medicine (listed in section 6 of this leaflet).
  • If you are currently taking any of the following medicines:
  • rifampicin and rifabutin(antibiotics used to treat infections, including tuberculosis);
  • St. John's Wort(a herbal medicine used to treat depression);
  • carbamazepine, phenobarbital and phenytoin(medicines used to treat epilepsy and prevent seizures);
  • rosuvastatin(a medicine used to treat high cholesterol levels).
  • If any of these apply to you, do not take Harvoni and tell your doctor immediately.

Warnings and precautions

Your doctor will know if you have any of the following conditions. They will be taken into account before starting treatment with Harvoni.

  • other liver problemsapart from hepatitis C, for example
  • if you are waiting for a liver transplant;
    • if you have had a hepatitis B virus infection in the past,as your doctor may want to monitor you more closely;
  • kidney problems or if you are on dialysis treatment,as Harvoni has not been fully studied in patients with severe kidney problems;
  • ongoing treatment for HIV infection,as your doctor may want to monitor you more closely.

Tell your doctor or pharmacist before starting treatment with Harvoni if:

  • you are currently taking or have recently stopped taking the medicine amiodarone to treat irregular heart rhythm, as it may cause a potentially life-threatening decrease in heart rate. Your doctor may consider alternative treatments if you have taken this medicine. If Harvoni treatment is needed, you may need additional heart monitoring.
  • you have diabetes. After starting Harvoni, you may need close monitoring of your blood glucose levels and/or adjustment of your diabetes medication. Some diabetic patients have experienced low blood sugar levels (hypoglycemia) after starting treatment with medicines like Harvoni.

Tell your doctor immediatelyif you are currently taking or have taken in the last few months any medicine for heart problems and, during treatment, you experience:

  • slow or irregular heartbeats, or heart rhythm problems;
  • shortness of breath or worsening of existing shortness of breath;
  • chest pain;
  • dizziness;
  • palpitations;
  • fainting or feeling like you are about to faint.

Blood tests

Your doctor will perform blood tests before, during, and after treatment with Harvoni. This is to:

  • allow your doctor to decide if you should take Harvoni and for how long;
  • allow your doctor to confirm that the treatment has worked and that you no longer have the hepatitis C virus.

Children and adolescents

Do not give this medicine to children under 3 years of age. The use of Harvoni has not been studied in children under 3 years of age.

Other medicines and Harvoni

Tell your doctor or pharmacistif you are taking, have recently taken or might take any other medicines.

Warfarin and other similar medicines known as vitamin K antagonists, used to thin the blood. Your doctor may increase the number of blood tests to check how your blood clots.

Your liver function may change with hepatitis C treatment, and this may affect other medicines (e.g. medicines used to suppress your immune system, etc.). Your doctor may need to closely monitor these other medicines you are taking and make adjustments after starting treatment with Harvoni.

If you are not sure if you should take any other medicine, ask your doctor or pharmacist.

Some medicines must not be taken with Harvoni.

  • Do not take any other medicine that contains sofosbuvir, one of the active substances of Harvoni.
  • Tell your doctor or pharmacistif you are taking any of the following medicines:
  • amiodarone,used to treat irregular heart rhythm
  • tenofovir disoproxil fumarateor any medicine that contains tenofovir disoproxil fumarate, used to treat HIV infection
  • digoxin,used to treat heart problems
  • dabigatran,used to thin the blood
  • statins,used to treat high cholesterol levels
  • rifapentine(an antibiotic used to treat infections, including tuberculosis)
  • oxcarbazepine(a medicine used to treat epilepsy and prevent seizures)
  • tipranavir(used to treat HIV infection).

Taking Harvoni with any of these medicines may stop them from working properly or make any side effects worse. Your doctor may need to give you a different medicine or adjust the dose of the one you are taking.

  • Ask your doctor or pharmacist for adviceif you are taking medicines used to treat stomach ulcers, heartburn or acid reflux.These include:
    • antacids (such as aluminium hydroxide/magnesium hydroxide or calcium carbonate). These medicines should be taken at least 4 hours before or 4 hours after Harvoni;
  • proton pump inhibitors (such as omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole). These medicines should be taken at the same time as Harvoni. Do not take proton pump inhibitors before Harvoni. Your doctor may give you a different medicine or adjust the dose of the one you are taking;
  • histamine H2-receptor antagonists (such as famotidine, cimetidine, nizatidine or ranitidine). Your doctor may give you a different medicine or adjust the dose of the one you are taking;

These medicines may reduce the amount of ledipasvir in the blood. If you are taking any of these medicines, your doctor will give you a different medicine for stomach ulcers, heartburn or acid reflux or advise you on how and when to take it.

Pregnancy and contraception

The effects of Harvoni during pregnancy are not known. If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

Pregnancy should be avoided if you are taking Harvoni with ribavirin. It is very important that you carefully read the section "Pregnancy" in the package leaflet of ribavirin. Ribavirin can be very harmful to the unborn baby. Special precautions should be taken in sexual activity if there is any possibility of pregnancy.

  • You or your partner must use an effective method of contraception during treatment with Harvoni and ribavirin and for some time after treatment. It is very important that you carefully read the section "Pregnancy" in the package leaflet of ribavirin. Ask your doctor for advice on an effective method of contraception that is suitable for you.
  • If you or your partner become pregnant during treatment with Harvoni and ribavirin or in the months after treatment, you should contact your doctor immediately.

Breast-feeding

Do not breast-feed during treatment with Harvoni.It is not known if ledipasvir or sofosbuvir, the two active substances of Harvoni, pass into human breast milk.

Driving and using machines

If you feel tired after taking Harvoni, do not perform activities that require concentration, such as driving, cycling or using machines.

Harvoni 90 mg/400 mg and 45 mg/200 mg film-coated tablets contain lactose

  • If your doctor has told you that you have an intolerance to some sugars, inform them before taking this medicine.

Harvoni 90 mg/400 mg film-coated tablets contain orange yellow S (E110) which may cause allergic reactions

  • Tell your doctor if you are allergicto orange yellow S (E110) before taking this medicine.

3. How to take Harvoni

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

Take this medicine exactly as your doctor has told you.

If you are not sure, ask your doctor or pharmacist.

Recommended dose

You must take Harvoni as directed by your doctor.The recommended dose of Harvoni in adultsis one 90 mg/400 mg film-coated tablet once a day. Your doctor will tell you how many weeks you need to take Harvoni.

The recommended dose of Harvoni in children aged 3 years and older is based on weight.

Take Harvoni as directed by your doctor.

Swallow the tablet(s) whole, with or without food. Do not chew, crush or break the tablet, as it has a very bitter taste. Tell your doctor or pharmacist if you have problems swallowing the tablets.

If you are taking an antacid,take it at least 4 hours before or at least 4 hours after Harvoni.

If you are taking a proton pump inhibitor,take the proton pump inhibitor at the same time as Harvoni. Do not take it before Harvoni.

If you vomit after taking Harvonithis may affect the amount of Harvoni in the blood. This may make Harvoni work less well.

  • If you vomit less than 5 hours aftertaking Harvoni, take another dose.
  • If you vomit more than 5 hours aftertaking Harvoni, you do not need to take another dose until your next scheduled dose.

If you take more Harvoni than you should

If you accidentally take more than the recommended dose, contact your doctor or the nearest emergency department immediately for advice. Take the pack of tablets with you to show the doctor what you have taken.

If you forget to take Harvoni

It is important that you do not miss any dose of this medicine.

If you miss a dose, calculate how long it has been since you took your last Harvoni:

  • If it is within 18 hoursof when you usually take Harvoni, take the dose as soon as possible. Then take the next dose at the usual time.
  • If it has been 18 hours or moresince you usually take Harvoni, wait and take the next dose at the usual time. Do not take a double dose (two doses in a short period of time).

Do not stop treatment with Harvoni

Do not stop treatment with this medicine unless your doctor tells you to. It is very important that you complete the full treatment course so that the medicine can work as well as possible to treat the hepatitis C virus infection.

If you have any other questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you take Harvoni, you may experience one or more of the following side effects:

Very common side effects

(may affect more than 1 in 10 people)

  • headache
  • fatigue

Common side effects

(may affect up to 1 in 10 people)

  • skin rash

Other side effects that may occur during treatment with Harvoni

The frequency of the following side effects cannot be estimated from the available data.

  • swelling of the face, lips, tongue or throat (angioedema).

Other side effects that may occur during treatment with sofosbuvir:

The frequency of the following side effects cannot be estimated from the available data.

  • widespread severe skin rash with skin peeling, possibly with fever, flu-like symptoms, blisters in the mouth, eyes and/or genitals (Stevens-Johnson syndrome).

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Harvoni

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after "EXP". The expiry date refers to the last day of the month stated.

This medicine does not require any special storage conditions.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Container Content and Additional Information

Composition of Harvoni

  • The active ingredients areledipasvir and sofosbuvir. Each film-coated tablet contains 90 mg of ledipasvir and 400 mg of sofosbuvir or 45 mg of ledipasvir and 200 mg of sofosbuvir.
  • The other ingredients are:Core of the tablet:

Copovidone, lactose monohydrate, microcrystalline cellulose, sodium croscarmellose, anhydrous colloidal silica, magnesium stearate

Film coating:

Polyvinyl alcohol, titanium dioxide, macrogol, talc, and only for the 90 mg/400 mg tablet; Orange Yellow FCF (E110)

Appearance of the Product and Container Content

Harvoni 90 mg/400 mg film-coated tablets are orange, rhombus-shaped tablets with "GSI" engraved on one side and "7985" on the other. The tablet measures approximately 19 mm in length and 10 mm in width.

Harvoni 45 mg/200 mg film-coated tablets are white, capsule-shaped tablets with "GSI" engraved on one side and "HRV" on the other. The tablet measures approximately 14 mm in length and 7 mm in width.

Each bottle contains a silica gel desiccant (drying agent) that should be kept in the bottle to help protect the tablets. The silica gel desiccant is packaged in a separate pouch or container and should not be swallowed.

The following package sizes are available:

  • 1 bottle of 28 film-coated tablets for 90 mg/400 mg and for 45 mg/200 mg film-coated tablets.
  • 3 bottles of 28 (84) film-coated tablets only for 90 mg/400 mg film-coated tablets. Not all package sizes may be marketed.

Marketing Authorization Holder

Gilead Sciences Ireland UC

Carrigtohill

County Cork, T45 DP77

Ireland

Manufacturer

Gilead Sciences Ireland UC

IDA Business & Technology Park

Carrigtohill

County Cork

Ireland

For further information on this medicinal product, please contact the local representative of the marketing authorization holder:

Belgium

Gilead Sciences Belgium SPRL-BVBA

Tel: + 32 (0) 24 01 35 50

Lithuania

Gilead Sciences Poland Sp. z o.o.

Tel: + 48 22 262 8702

Bulgaria

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Luxembourg

Gilead Sciences Belgium SPRL-BVBA

Tel: + 32 (0) 24 01 35 50

Czech Republic

Gilead Sciences s.r.o.

Tel: + 420 910 871 986

Hungary

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Denmark

Gilead Sciences Sweden AB

Tel: + 46 (0) 8 5057 1849

Malta

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Germany

Gilead Sciences GmbH

Tel: + 49 (0) 89 899890-0

Netherlands

Gilead Sciences Netherlands B.V.

Tel: + 31 (0) 20 718 36 98

Estonia

Gilead Sciences Poland Sp. z o.o.

Tel: + 48 22 262 8702

Norway

Gilead Sciences Sweden AB

Tel: + 46 (0) 8 5057 1849

Greece

Gilead Sciences Ελλάς Μ.ΕΠΕ.

Tel: + 30 210 8930 100

Austria

Gilead Sciences GesmbH

Tel: + 43 1 260 830

Spain

Gilead Sciences, S.L.

Tel: + 34 91 378 98 30

Poland

Gilead Sciences Poland Sp. z o.o.

Tel: + 48 22 262 8702

France

Gilead Sciences

Tel: + 33 (0) 1 46 09 41 00

Portugal

Gilead Sciences, Lda.

Tel: + 351 21 7928790

Croatia

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Romania

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Ireland

Gilead Sciences Ireland UC

Tel: + 353 (0) 214 825 999

Slovenia

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Iceland

Gilead Sciences Sweden AB

Tel: + 46 (0) 8 5057 1849

Slovakia

Gilead Sciences Slovakia s.r.o.

Tel: + 421 232 121 210

Italy

Gilead Sciences S.r.l.

Tel: + 39 02 439201

Finland

Gilead Sciences Sweden AB

Tel: + 46 (0) 8 5057 1849

Cyprus

Gilead Sciences Ελλάς Μ.ΕΠΕ.

Tel: + 30 210 8930 100

Sweden

Gilead Sciences Sweden AB

Tel: + 46 (0) 8 5057 1849

Latvia

Gilead Sciences Poland Sp. z o.o.

Tel: + 48 22 262 8702

United Kingdom

Gilead Sciences Ltd.

Tel: + 44 (0) 8000 113700

Date of Last Revision of this Leaflet:

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu

Online doctors for HARVONI 90 mg/400 mg FILM-COATED TABLETS

Discuss questions about HARVONI 90 mg/400 mg FILM-COATED TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
0.0 (0)
Doctor

Daniel Cichi

Family medicine 24 years exp.

Dr Daniel Cichi is a family medicine doctor with over 20 years of clinical experience. He provides online consultations for adults, supporting patients with acute symptoms, chronic conditions, and everyday health concerns that require timely medical guidance.

His background includes work in emergency care, ambulance services, and family medicine, which allows him to assess symptoms quickly, identify warning signs, and help patients choose the safest next steps – whether that means home care, treatment adjustment, or in-person evaluation.

Patients commonly consult Dr Daniel Cichi for:

  • acute symptoms: fever, infections, flu-like illness, cough, sore throat, shortness of breath;
  • chest discomfort, palpitations, dizziness, fatigue, and blood pressure concerns;
  • digestive problems: abdominal pain, nausea, diarrhoea, constipation, reflux;
  • muscle, joint, and back pain, minor injuries, post-traumatic symptoms;
  • chronic conditions: hypertension, diabetes, high cholesterol, thyroid disorders;
  • review and interpretation of lab tests, imaging reports, and medical documents;
  • medication review and treatment adjustment;
  • medical advice while travelling or living abroad;
  • second opinions and guidance on whether in-person care is needed.
Dr Cichi’s consultations are structured and practical. He focuses on clear explanations, risk assessment, and actionable recommendations, helping patients understand their symptoms and make informed decisions about their health.
Camera Book a video appointment
€55

Frequently Asked Questions

Is a prescription required for HARVONI 90 mg/400 mg FILM-COATED TABLETS?
HARVONI 90 mg/400 mg FILM-COATED TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in HARVONI 90 mg/400 mg FILM-COATED TABLETS?
The active ingredient in HARVONI 90 mg/400 mg FILM-COATED TABLETS is sofosbuvir and ledipasvir. This information helps identify medicines with the same composition but different brand names.
Who manufactures HARVONI 90 mg/400 mg FILM-COATED TABLETS?
HARVONI 90 mg/400 mg FILM-COATED TABLETS is manufactured by Gilead Sciences Ireland Unlimited Company. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of HARVONI 90 mg/400 mg FILM-COATED TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether HARVONI 90 mg/400 mg FILM-COATED TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to HARVONI 90 mg/400 mg FILM-COATED TABLETS?
Other medicines with the same active substance (sofosbuvir and ledipasvir) include EPCLUSA 150 mg/37.5 mg COATED GRANULES IN SACHET, EPCLUSA 200 mg/50 mg COATED GRANULES IN SACHET, EPCLUSA 400 MG/100 MG FILM-COATED TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media